The synergistic effects of the combination therapy could be explained by a multiple phases process: firstly, PARP inhibition directly induces tumor cell damage, which increases the neoantigen load and therefore an antitumor T-cell response, a process that is amplified by ICI blockade. This evidence concerns the gene PARP1 and neoplasm.